🟢 Capricor Therapeutics is trading 5.7% up in pre-market with no clear company-specific catalyst

Capricor Therapeutics is trading 5.7% up at $6.65, with no new company-specific announcement clearly explaining the August 24 pre-market rise.

• The stock had a highly volatile week, including a 57.96% gain on August 14 followed by sharp declines.
• Recent coverage highlights ongoing uncertainty around deramiocel’s FDA review and activist investor pressure.
• Broader U.S. futures are lower, so the move does not appear aligned with overall market sentiment.